Percutaneous balloon mitral commissurotomy during pregnancy

Mohamed Ben Farhat, Habib Gamra, Fethi Betbout, Faouzi Maatouk, Mourad Jarrar, Faouzi Addad, Mabrouk Tiss, Sonia Hammami, Iheb Chahbani, Rafik Thaalbi

Abstract

Objective—To evaluate the effectiveness and safety of percutaneous balloon mitral commissurotomy for the treatment of pregnant women with severe mitral stenosis over a period of six years.

Design—Analysis of clinical, haemodynamic, and echocardiographic data before and immediately after the procedure, the pregnancy outcome, and the fate of newborn babies.

Setting—Academic cardiovascular centre in Monastir, Tunisia.

Patients—44 pregnant patients who underwent percutaneous transvenous dilatation of the mitral valve between January 1990 and February 1996. Grade 2 mitral regurgitation was present in two patients and densely calcic valves in three (7%).

Results—Commissurotomy was successfully achieved in all cases. The total mean (SD) duration of the procedure was 72 (18) minutes and that of fluoroscopy 16 (7) minutes. Left atrial pressure decreased from 28 (10) to 14 (7) mm Hg, mitral pressure gradient fell from 22 (8) to 5 (3) mm Hg. Cardiac output increased from 4·8 (1·1) to 6·3 (1·2) l/min and Gorlin mitral valve area from 0·96 (0·21) to 2·4 (0·4) cm² (all P < 0·001). Cross sectional echocardiographic mitral valve area increased from 1·07 (0·21) to 2·32 (0·36) cm². There were no maternal or fetal deaths. Complications included a grade 4 mitral regurgitation in one patient that required early valve replacement. All patients delivered at full term, 42 vaginally and two (5%) by caesarean section; 41 babies were normal and three whose mothers had the procedure near term were relatively hypotrophic. At a mean follow up of 28 (12) months (range 2 to 26) all children had normal growth.

Conclusions—During pregnancy, balloon mitral commissurotomy is the treatment of choice of severe pliable mitral stenosis in patients who are refractory to medical treatment.

(Heart 1997;77:564–567)

Keywords: balloon mitral commissurotomy; pregnancy

Normal pregnancy is associated with an adaptational circulatory state including primarily a 40–50% increase in cardiac output and decrease in systemic vascular resistance. In the presence of severe mitral stenosis, these beneficial changes do not occur despite a dangerous rise in left atrial pressure. The increased blood volume and tachycardia aggravate the venocapillary pulmonary congestion. Thus incipient pulmonary oedema can occur, particularly in the peripartum period. Since the initial description by Inoue et al in 1984 of percutaneous transvenous balloon mitral commissurotomy, numerous large series have established the efficacy and safety of this procedure. However, its use during pregnancy remained limited to nearly 100 cases. We report the results of this technique in 44 pregnant women with rheumatic mitral stenosis.

Methods

PATIENTS

Of 549 consecutive patients who underwent balloon mitral commissurotomy in our department from November 1987 to February 1996, 44 were pregnant (8% of overall group, 11% of women). Their mean (SD) age was 29 (6) years (range 18 to 43 years). Length of pregnancy varied from 15 to 37 weeks, mean 26 (6) weeks. Forty patients (91%) were in sinus rhythm and the remaining four were in atrial fibrillation. Four patients had a previous surgical commissurotomy and four others had a previous balloon mitral commissurotomy. Despite medical treatment including bed rest, frusemide, and digoxin (only two patients who had uncontrolled heart rate with digitalis were given atenolol), 15 patients (34%) remained in New York Heart Association (NYHA) functional class IV and 25 patients (57%) in class III. The four remaining patients initially had severe disability that improved to functional class II. Two of them had an echo mitral valve area (MVA) of 1·0 cm² and 1·2 cm², respectively. In the two others who had an echo MVA of 1·4 and 1·5 cm², respectively, the procedure was undertaken because of a history of spontaneous miscarriage during the third trimester of previous pregnancies. In four patients, the procedure had to be performed within 48 hours of admission because of severe refractory pulmonary oedema.

ECHOCARDIOGRAPHIC STUDY

Cross sectional, pulsed, colour, and continuous wave Doppler echocardiographic examinations were performed 24 hours before and 24 hours after balloon mitral commissurotomy, and at four to six month intervals of fol-
Percutaneous balloon mitral commissurotomy during pregnancy

### Table 1: Haemodynamic results before and immediately after balloon mitral commissurotomy

<table>
<thead>
<tr>
<th></th>
<th>Before (mean ± SD)</th>
<th>After (mean ± SD)</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beats/min)</td>
<td>86 (13)</td>
<td>82 (10)</td>
<td>NS</td>
</tr>
<tr>
<td>Pressures (mm Hg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean left atrial</td>
<td>28 (10)</td>
<td>14 (7)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Mean mitral gradient</td>
<td>22 (8)</td>
<td>5 (3)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Pulmonary artery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>56 (24)</td>
<td>36 (16)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Diastolic</td>
<td>29 (11)</td>
<td>17 (9)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Mean</td>
<td>41 (18)</td>
<td>25 (12)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Aoorta</td>
<td>105 (10)</td>
<td>107 (10)</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic</td>
<td>67 (7)</td>
<td>68 (8)</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>86 (8)</td>
<td>86 (9)</td>
<td>NS</td>
</tr>
<tr>
<td>Cardiac index (f/min/mm²)</td>
<td>3.0 (0.69)</td>
<td>3.9 (0.77)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Mitral valve area (cm²)</td>
<td>0.96 (0.21)</td>
<td>2.43 (0.43)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Pulmonary vascular resistance (dyne.s.cm⁻²)</td>
<td>710 (389)</td>
<td>364 (214)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Arterial</td>
<td>256 (216)</td>
<td>166 (156)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Systemic vascular resistance (dyne.s.cm⁻²)</td>
<td>1409 (309)</td>
<td>1091 (230)</td>
<td>0.00001</td>
</tr>
</tbody>
</table>

CARDIAC CATHETERISATION AND BALLOON COMMISSUROTOMY TECHNIQUE

The procedure was approved by the ethics committee of our institution, and informed consent was obtained from the 44 patients and their husbands. During the procedure, the patients’ pelvic abdominal area was shielded in order to protect the fetus from radiation. To minimise radiation exposure, left ventriculography was not performed. Fluoroscopy was used only when necessary. The procedure was performed in the fasting state and with premedication (10 mg clorazepate intravenously) and local anaesthesia. Right and left sided cardiac catheterisation was performed from the left groin. Heparin was given (100 IU/kg body weight) after transseptal catheterisation. Two Triad-AT balloon catheters (Boston Scientific Corporation, Watertown, MA, USA; balloon diameter 18 and 20 mm) were used in 41 patients. The Inoue device (Toray Industries, Tokyo, Japan) was used in three patients.

### Table 2: Characteristics of the four patients in NYHA class II before and after balloon mitral commissurotomy

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echo score</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Echographic mitral valve area (cm²)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>1-0</td>
<td>2-5</td>
<td>1-4</td>
<td>2-2</td>
<td>1-5</td>
</tr>
<tr>
<td>30</td>
<td>10</td>
<td>18</td>
<td>17</td>
<td>35</td>
</tr>
<tr>
<td>Mitral pressure gradient (mm Hg)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Cardiac index (m/min/mm²)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>2-5</td>
<td>2-8</td>
<td>2-9</td>
<td>3-8</td>
<td>4-7</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association grade; pre/post, before/after commissurotomography.

### Table 3: Characteristics of the three patients with severe valvar calcifications

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echo score</td>
<td>12</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>Echographic mitral valve area (cm²)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>0-7</td>
<td>1-8</td>
<td>1</td>
<td>2-1</td>
</tr>
<tr>
<td>41</td>
<td>20</td>
<td>38</td>
<td>20</td>
</tr>
<tr>
<td>Mitral pressure gradient (mm Hg)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>28</td>
<td>9</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>Cardiac index (m/min/mm²)</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>2-8</td>
<td>3-8</td>
<td>2-6</td>
<td>3-7</td>
</tr>
</tbody>
</table>

Pre/post, before/after mitral commissurotomy.

Results

IMMEDIATE RESULTS

There was no technical failure. The duration of the procedure varied from 54 to 100 minutes, mean (SD) 72 (18), and the fluoroscopy time was 16 (7) minutes (range 7 to 26). As shown in table 1, major haemodynamic improvement and highly significant increase in MVA from 0.96 to 2.43 cm² by the Gorlin formula were obtained. MVA, as determined by cross sectional echocardiography, increased from 1.07 (0.21) to 2.32 (0.36) cm², and as determined by the Doppler method it increased from 1.03 (0.22) to 2.32 (0.22) cm². No patient was left with residual mitral stenosis (MVA < 1.5 cm²).

Table 2 gives the baseline characteristics and major haemodynamic changes in the four patients who were in NYHA functional class II before balloon mitral commissurotomy. Baseline features and results were very similar to those of the whole group. In patients with severe calcium deposits on fluoroscopy, an acceptable increase in MVA and cardiac index was obtained, as well as a significant decrease in left atrial pressure (table 3). Precommissurotomy grade 2 mitral regurgitation—which was present in two cases—remained unchanged, whereas MVA, as determined by cross sectional echo, increased to 2.3 cm² in both cases and left atrial pressure decreased to 14 and 16 mm Hg respectively. Two other patients developed a grade 2 mitral regurgitation which was well tolerated. There were no deaths or peripheral emboli. Complications included a grade 4 mitral regurgitation in one patient which required early mitral valve replacement, and an incomplete femoral vein thrombosis in another patient, which resolved with heparin treatment. Four patients (9%) had a trivial to moderate left to right interatrial shunt with a pulmonary to systemic flow ratio (Qp/Qs) of < 1:4:1.

POSTCOMMISSUROTOMY COURSE

All patients, including the one who received early mitral valve replacement, had a substantial functional improvement which allowed discontinuation of diuretics in all but the four patients with grade 2 mitral regurgitation. Digoxin was continued in those four patients and in the four patients with atrial fibrillation. Acenocoumarol was given until the 37th week of gestation to the four patients in atrial fibrillation and to the patient who received mitral valve replacement; after this it was replaced by

---

The text contains a detailed description of the procedure and its outcomes, including hemodynamic data, and refers to various tables and figures that provide further details. The results section highlights the improvements in MVA and left atrial pressure, along with the absence of significant complications and the functional recovery of the patients.
subcutaneous heparin. The 44 women all had a spontaneous full term delivery, vaginally in 42 and by caesarean section in two for obstetrical reasons. The 44 newborn babies were healthy, without any evidence of fetal abnormality caused by radiation. Mean body weight of the babies was 3.2 (0.45) kg, range 2.0 to 4.4.

Three women who underwent balloon mitral commissurotomy late in pregnancy (after the 30th week of gestation) delivered hypotrophic babies (body weight between 2 and 2.5 kg).

At a mean follow up of 30 (16) months (range 6 to 72), 40 patients (91%) remained in functional class I, three patients were in class II, and one patient with a severely calcified valve returned to class IV, with severe mitral stenosis which required mitral valve replacement. Overall, MVA as assessed by cross sectional echo decreased from 2.32 (0.36) to 2.17 (0.40) cm² (P < 0.05). At a mean postpartum follow up of 28 (12) months (range 2 to 66), the 44 infants had shown normal growth and development.

Discussion
Since the initial description by Inoue et al,2 numerous large series have proved the efficacy and safety of balloon mitral commissurotomy as a treatment of rheumatic mitral stenosis.1,12

BALLOON MITRAL COMMISSUROTOMY DURING PREGNANCY
Successful double balloon mitral commissurotomy during pregnancy was first reported in 1988 by Safian et al11 and Palacios et al.14 The use of this new procedure during pregnancy has remained limited, and among the 11 reports12-22 documenting about 100 cases, only one included 19 patients.18 For the best of our knowledge, our series is the largest reported with complete pre- and postprocedural haemodynamic assessment. As reported in these other studies, in our series balloon mitral commissurotomy produced impressive haemodynamic improvement including a decrease in left atrial and pulmonary artery pressures, a fall in pulmonary and systemic vascular resistance, and an increase in cardiac output and mitral valve area.

One of the crucial changes that affects the subsequent course of gestation is likely to be the significant increase in cardiac output (1.5 l/min in this study). Most of our patients had a pliable mitral valve with mild or no mitral regurgitation, which represent the ideal anatomy for balloon mitral commissurotomy. With the benefit of the experience we have acquired, we broadened our indications to include three patients with a densely calcified mitral valve and two with a pliable mitral valve but with a grade 2 mitral regurgitation. Very satisfactory results were obtained in all those five cases. Other large studies12 including our own have also reported satisfactory results in many patients with calcific valves. With respect to grade 2 mitral regurgitation, although this remained unchanged in our two patients, we believe that in such cases balloon mitral commissurotomy should be performed with great caution and with adequate surgical back up.

Very few complications have been reported with balloon mitral commissurotomy during pregnancy. New severe mitral regurgitation occurred in only one patient of our series, who underwent a successful prosthetic mitral valve replacement. In one report, one patient had a spontaneous abortion.20 Occasionally17,19 ominous hypotension requiring administration of drugs and fluids occurred. A left to right interatrial shunt was more common, but it was too small to have any immediate or late consequences. There were no maternal deaths in our series or in the previous reports.12-22 In contrast, mortality from surgical closed mitral commissurotomy was as high as 3%24-28 and that from open commissurotomy reached 5%.29-30

EFFECT OF BALLOON MITRAL COMMISSUROTOMY ON PREGNANCY OUTCOME
Highly significant functional improvement paralleled haemodynamic improvement in all patients: frusenide was discontinued in 90% of patients and digoxin in 81%. Forty patients returned to class I and four to class II. Uneventful full term delivery was obtained in all patients, vaginally in 42; caesarean section was required in only two patients (5%) for obstetric reasons. The relative growth retardation in three newborns probably reflected the lateness of the procedure in these cases, but this needs further investigation to be confirmed.

There were no fetal deaths or perterm deliveries in our series. However, in previous studies, three neonatal fatalities have been reported; all three were related to particular circumstances: a premature birth,13 an obstetric factor,19 and a genemellar pregnancy.20 Following surgical closed mitral commissurotomy,24-26 the prematurity rate varied from 10% up to 37%, and fetal mortality ranged from 0% up to 15%. Open heart commissurotomy carries a higher risk of 20–30% fetal wastage.27-30

Fluoroscopic radiation exposure carries a potential risk to the unborn child. However, the risk is greatly diminished by appropriate and complete abdominal lead shielding, a short radiation exposure time, avoidance of left ventricular angiography, and performance of the procedure after the 14th week of gestation, when organogenesis has already been achieved. In previous reports, as in our own, no baby had abnormalities related to radiation.

The double balloon technique was used in most of our patients and the Inoue balloon, which was not available in our centre until recently, was used in only three patients, with similar results to the others. The Inoue balloon technique seems to shorten the fluoroscopy time18 and therefore appears very attractive in this particular setting. The fluoroscopy time in our series was similar to that reported by Ribeiro et al17 who used the Inoue balloon technique. Patel et al18 reported a shorter fluoroscopy time but they did not
record the haemodynamic measurements which certainly contribute to the shortening of the procedure. The total radiation dose has sometimes been estimated and has always been lower than 0-2 rads, far below the dose at which therapeutic abortion can legally be carried out. It is noteworthy that the 44 infants in this study had normal growth and mental development at an intermediate follow up. Twenty children are now 3 to 5 years old and are in excellent health. As yet, however, the long term outcome in these children remains unknown. Hence there is no evidence that radiation side effects cannot be excluded, though it must be very unlikely. Grieö et al.11 in a 20 year follow up study of 1000 women irradiated for radiopelviometry at much higher doses (15 to 30 mSv), found no difference in the incidence of cancer in comparison with a control group.

MEDICAL TREATMENT FOR MITRAL STENOSIS DURING PREGNANCY

Although medical treatment is always recommended as first line therapy of mitral stenosis during pregnancy before considering balloon mitral valvulotomy, the untoward effects of some drugs in this particular setting should be borne in mind.

Diuretics, which are very effective, are known on the other hand to decrease placental perfusion and therefore are not recommended during pregnancy. β-Blockers, which can be very beneficial during pregnancy, also carry some risk, particularly in patients with severe pulmonary hypertension and low cardiac output. Some studies have failed to show any clear benefit of β-blockers in non-pregnant patients with mitral stenosis,41 42 while others43 44 have reported serious adverse effects on the fetus and neonate (intratracheal growth retardation, cardiomyopathy, hyperbilirubinemia) with the use of these agents during pregnancy.

Thus balloon valvulotomy seems to be an excellent alternative to drug treatment. However, until greater experience is acquired, balloon mitral valvulotomy during pregnancy should be confined to patients with severe mitral stenosis who are refractory to optimum medical treatment.

Note added in proof: Since this paper was submitted, we have successfully performed six more balloon mitral valvulotomies during pregnancy.

We thank Jamila Rassas for manuscript preparation.

Percutaneous balloon mitral commissurotomy during pregnancy.


*Heart* 1997 77: 564-567
doi: 10.1136/hrt.77.6.564

Updated information and services can be found at:
http://heart.bmj.com/content/77/6/564

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Mitral valve disease (229)
- Clinical diagnostic tests (4779)
- Echocardiography (2127)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/